Denmark first suspended the use of the AstraZeneca vaccine on March 11, citing "very rare but severe side effects" discovered during the jab's safety monitoring.
Denmark's decision on Wednesday came in the wake of the European Medical Agency's (EMA) recent verdict that "the benefits of using the Covid-19 vaccine from AstraZeneca continue to outweigh the risks for people who receive it".
The Danish Health Authority agrees with the EMA's general findings, Brostrom said, adding that "in the midst of an epidemic, it has been a difficult decision to continue our vaccination program without an effective and readily available vaccine against Covid-19".
However, the authority referred to further comments by the EMA that the "use of the vaccine during vaccination campaigns at the national level should also consider the pandemic situation and vaccine availability in each individual country".
"We are basically in agreement with the EMA's assessment regarding the AstraZeneca vaccine. That is why it is important to emphasize that it is still an approved vaccine," said Brostrom.
"But if Denmark were in a completely different situation and in the midst of a violent third outbreak and if we had not reached such an advanced point in our rollout of the vaccines, then I would not hesitate to use the vaccine, even if there were rare but severe complications associated with using it."
According to the Statens Serum Institut's (SSI) updated overview, 149,884 people in Denmark have received at least one shot and 596 both shots of AstraZeneca's Covid-19 vaccine.
"Those who have received the first injection with AstraZeneca will later receive an invitation to vaccination with another vaccine," the health authority said.
Meanwhile, Denmark continues to administer the vaccines produced by Pfizer/BioNTech and Moderna.
In total, 995,672 Danes have received at least one shot of a vaccine, which corresponds to 17 per cent of the population, the SSI said on Wednesday.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.